Abstract | PURPOSE: METHODS AND MATERIALS: From May 1998 to May 2001, 62 consecutive patients with cT(3-4) or cN(+) rectal cancer, or both, were treated with 45-50 Gy (1.8 Gy/day; 25 fractions) and oral tegafur 1200 mg/day. Surgery was performed 6 weeks after the completion of chemoradiation. All patients received a boost with intraoperative electron beam radiotherapy (IOERT) over the presacral space. RESULTS: Grade 3-4 hematologic toxicity consisted on Grade 3 anemia in 1 patient. Nonhematologic toxicity was mild. Fifteen patients (23%) had Grade 3 dermatitis, 16 (25%) had Grade 3, and 2 (3%) had Grade 4 proctitis. The median dose of radiotherapy was 50.4 Gy. Surgery consisted on anterior resection in 38 patients (61%) and abdominoperineal amputation in 24 (39%). Five complete pathologic responses were observed (8%), and 29 patients (47%) had a minimal microscopic residual tumor (mic category). The total downstaging rate was 68%. With a median follow-up of 46 months, the pelvic control rate was 95%, disease-free survival 74.1%, and overall survival 76.5%. CONCLUSIONS:
|
Authors | Juan A Díaz-González, Felipe A Calvo, Javier Cortés, Dolores de La Mata, Marina Gómez-Espí, Miguel A Lozano, Esperanza Lozano, Javier Serrano, Rafael Herranz |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 61
Issue 5
Pg. 1378-84
(Apr 01 2005)
ISSN: 0360-3016 [Print] United States |
PMID | 15817340
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Tegafur
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
(adverse effects, methods)
- Neoplasm Staging
- Radiotherapy Dosage
- Rectal Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Survival Analysis
- Tegafur
(therapeutic use)
|